Literature DB >> 22618955

Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.

Daphne D Dadzie1, Esther J Lee, Catherine A Monteleone, Stephen H Schneider.   

Abstract

Octreotide is widely used as medical therapy for acromegaly. It is known to markedly reduce growth hormone levels, improve symptoms and reduce tumor size. Common side effects include gastrointestinal symptoms, hepatobiliary disorders, dizziness, headaches, bradycardia, hyperglycemia or hypoglycemia and thyroid dysfunction. Although urticaria, allergy/hypersensitivity reactions and anaphylaxis have been noted as possible adverse reactions, there is a lack of data showing a causal relationship between octreotide and hypersensitivity reactions and there is no information on management when continued use of this medication is essential. We now report a case of a 60 year old male with acromegaly who had presented with a cutaneous hypersensitivity reaction to octreotide. In addition he failed treatment with surgery, radiation, and dopamine agonist and could no longer afford to continue treatment with pegvisomant. The patient underwent desensitization treatment for his octreotide allergy and was able to resume treatment without any further side effects. We believe this case represents the first report of successful desensitization treatment for octreotide allergy in an acromegalic patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22618955     DOI: 10.1007/s11102-012-0400-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  34 in total

Review 1.  Somatostatin analogs in acromegaly.

Authors:  Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

2.  AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.

Authors:  David M Cook; Shereen Ezzat; Laurence Katznelson; David L Kleinberg; Edward R Laws; Todd B Nippoldt; Brooke Swearingen; Mary Lee Vance
Journal:  Endocr Pract       Date:  2004 May-Jun       Impact factor: 3.443

Review 3.  Role of T cells in drug allergies.

Authors:  W J Pichler; B Schnyder; M P Zanni; Y Hari; S von Greyerz
Journal:  Allergy       Date:  1998-03       Impact factor: 13.146

4.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Authors:  A Colao; P Marzullo; D Ferone; V Marinò; R Pivonello; C Di Somma; A Di Sarno; A Giaccio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

5.  Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.

Authors:  M Suliman; R Jenkins; R Ross; T Powell; R Battersby; D R Cullen
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

6.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.

Authors:  P Caron; I Morange-Ramos; M Cogne; P Jaquet
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

Review 8.  Allergic reactions to drugs and biologic agents.

Authors:  R D deShazo; S F Kemp
Journal:  JAMA       Date:  1997-12-10       Impact factor: 56.272

9.  Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.

Authors:  I Morange; F De Boisvilliers; P Chanson; B Lucas; D DeWailly; F Catus; F Thomas; P Jaquet
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

10.  Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide.

Authors:  J Marek; V Hána; M Krsek; V Justová; F Catus; F Thomas
Journal:  Eur J Endocrinol       Date:  1994-07       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.